Eledon Pharmaceuticals Reports Positive Data in Type 1 Diabetes Study; Shares Rise

MT Newswires Live10-29

Eledon Pharmaceuticals (ELDN) reported positive initial data from a diabetes study after the first two of three islet transplant recipients achieved insulin independence at three months post-transplant.

The subjects were treated with an immunosuppression regimen that includes tegoprubart, Eledon's investigational anti-CD40L antibody, aimed at preventing islet transplant rejection in individuals with type 1 diabetes.

The trial showed the potential first human cases of the achievement of insulin independence using an anti-CD40L monoclonal antibody therapy without tacrolimus, the current standard of care to prevent transplant rejection, the company said Tuesday in a statement.

The third subject lowered insulin use by 60% three days after receiving an islet transplant and remains on track for insulin independence, the company said.

The company said treatment with tegoprubart was generally well-tolerated.

Eledon shares rose 11% in recent Tuesday trading.

Price: 3.75, Change: +0.38, Percent Change: +11.28

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479528294?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 23:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479528294","market":"fut","top_or_hot":-1,"title":"Eledon Pharmaceuticals Reports Positive Data in Type 1 Diabetes Study; Shares Rise","media":"MT Newswires Live","content":"<html><body><p> Eledon Pharmaceuticals (ELDN) reported positive initial data from a diabetes study after the first two of three islet transplant recipients achieved insulin independence at three months post-transplant.</p><p>The subjects were treated with an immunosuppression regimen that includes tegoprubart, Eledon's investigational anti-CD40L antibody, aimed at preventing islet transplant rejection in individuals with type 1 diabetes.</p><p>The trial showed the potential first human cases of the achievement of insulin independence using an anti-CD40L monoclonal antibody therapy without tacrolimus, the current standard of care to prevent transplant rejection, the company said Tuesday in a statement.</p><p>The third subject lowered insulin use by 60% three days after receiving an islet transplant and remains on track for insulin independence, the company said.</p><p>The company said treatment with tegoprubart was generally well-tolerated.</p><p>Eledon shares rose 11% in recent Tuesday trading.</p><p>Price: 3.75, Change: +0.38, Percent Change: +11.28</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eledon Pharmaceuticals Reports Positive Data in Type 1 Diabetes Study; Shares Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEledon Pharmaceuticals Reports Positive Data in Type 1 Diabetes Study; Shares Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eledon Pharmaceuticals (ELDN) reported positive initial data from a diabetes study after the first two of three islet transplant recipients achieved insulin independence at three months post-...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELDN","symbol_name":"Eledon Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479528294","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479528294","pubTimestamp":1730214229,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eledon Pharmaceuticals  reported positive initial data from a diabetes study after the first two of three islet transplant recipients achieved insulin independence at three months post-transplant.The subjects were treated with an immunosuppression regimen that includes tegoprubart, Eledon's investigational anti-CD40L antibody, aimed at preventing islet transplant rejection in individuals with type 1 diabetes.The trial showed the potential first human cases of the achievement of insulin independence using an anti-CD40L monoclonal antibody therapy without tacrolimus, the current standard of care to prevent transplant rejection, the company said Tuesday in a statement.The third subject lowered insulin use by 60% three days after receiving an islet transplant and remains on track for insulin independence, the company said.The company said treatment with tegoprubart was generally well-tolerated.Eledon shares rose 11% in recent Tuesday trading.Price: 3.75, Change: +0.38, Percent Change: +11.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELDN":"Eledon Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Eledon Pharmaceuticals报告1型糖尿病研究的积极数据；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELDN":0.9},"content_text":"Eledon Pharmaceuticals (ELDN) reported positive initial data from a diabetes study after the first two of three islet transplant recipients achieved insulin independence at three months post-transplant.The subjects were treated with an immunosuppression regimen that includes tegoprubart, Eledon's investigational anti-CD40L antibody, aimed at preventing islet transplant rejection in individuals with type 1 diabetes.The trial showed the potential first human cases of the achievement of insulin independence using an anti-CD40L monoclonal antibody therapy without tacrolimus, the current standard of care to prevent transplant rejection, the company said Tuesday in a statement.The third subject lowered insulin use by 60% three days after receiving an islet transplant and remains on track for insulin independence, the company said.The company said treatment with tegoprubart was generally well-tolerated.Eledon shares rose 11% in recent Tuesday trading.Price: 3.75, Change: +0.38, Percent Change: +11.28","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479528294"}